DIR — Lanton Law Blog

Lanton Law Speaks with Pharmacy Times About the Mark Cuban Cost Plus Drug Company

Lanton Law spoke with Pharmacy Times about the possible market implications of the new Mark Cuban Cost Plus Drug Company.

pharmacy, pharmaceuticals, pharmacy benefit manager, prescription drug costs, Congress, healthcareRon LantonJanuary 27, 2022Mark Cuban Cost Plus Drug Company, pharmacy, Pharmacy Benefit Manager, drug wholesale, manufacturer, DIR, mail order pharmacy

New Proposed Congressional DIR Relief Bill

At Lanton Law we are constantly on the watch for issues impacting our specialty, retail and LTC pharmacy clients including the issue of DIR fees. Clients utilize our advocacy and legal tools while discussing business strategy to combat an ever changing reimbursement environment.

pharmacy, pharmacy benefit manager, pharmaceuticals, specialty pharmacy, LTC, life sciences, Long term care pharmacy, insurance, healthcareRon LantonJune 17, 2021Pharmacy DIR Reform to Reduce Senior Drug Costs Act, DIR, Pharmacy, PBM, direct and indirect remuneration fees

National Community Pharmacists Association (NCPA) Files Lawsuit Against HHS Seeking to Eliminate Pharmacy DIR Fees

NCPA has sued the Department of Health and Human Services (HHS) over DIR fees. The lawsuit can be viewed here.

CMS, healthcare, HHS, pharmaceuticals, pharmacy, pharmacy benefit manager, prescription drug costs, regulation, lobbyist, legislatureRon LantonJanuary 19, 2021pharmacy, DIR, National Community Pharmacists Association

Pharmacy Times Interviews Lanton Law On How COVID-19 May Lead to the Expansion of Practice Laws for Pharmacists Across the Country

Alana Hippensteele; Editor, MA of Pharmacy Times interviewed Ron Lanton to discuss how COVID-19 may lead to expansion of practice laws for pharmacists across the country.

Lanton Law Interviews the Massachusetts Pharmacists Association on DIR & Provider Status

We are excited to have Lindsay De Santis; Executive Vice President of the Massachusetts Pharmacists Association (MPhA) do a blogcast with us. Our conversation covers pharmacy DIR (direct and indirect remuneration) fees, pharmacy provider status and COVID-19.

life sciences, pharmaceuticals, pharmacy, reimbursement, Medicare Part B, Medicare Part DRon LantonMay 19, 2020DIR fee, DIR, direct and indirect remuneration fees, pharmacy provider status, provider status, COVID-19, Massachusetts, Massachusetts Pharmacists Association